Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quizartinib Looks Like A Good Drug, ODAC Says, But Needs Another Efficacy Trial Before Approval

Executive Summary

US FDA's Oncologic Drugs Advisory Committee voted 8-3 against approval for Daiichi's quizartinib, although panelists felt the acute myeloid leukemia candidate would be approvable with another trial to better characterize its efficacy.
Advertisement

Related Content

Pink Sheet Podcast: Oncology Reviews, Biosimilars, and More Biosimilars
Recent And Upcoming FDA Advisory Committee Meetings
Defining REMS Success An Unanswered Question For Daiichi's Pexidartinib
Daiichi's AML Drug Quizartinib Heads To ODAC With Host Of Efficacy, Safety Issues

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS125285

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel